Genotyping and Phylogenetic Analysis of Human Papillomaviruses in Formalin Fixed Paraffin Embedded Sections from Cervical Lesions in Duhok-Iraq

Objective: Human papillomavirus (HPV) has been identified as an important causative factor in cervical cancer development. Cervical cancer is the fourth most prevalent malignant tumor among women globally. The purpose of this study was to investigate the prevalence and genotyping sequences of HPV in formalin-fixed paraffin-embedded (FFPE) cervical tissue using conventional polymerase chain reaction (PCR), and HPV-DNA sequencing. Material and Methods: Retrospective cross-sectional study. Forty (FFPE) blocks with different cervical lesions were taken; patients’ ages ranged from 24 to 65 years. Detection and sequencing of HPV DNA were done by conventional PCR (L1 gene), which was achieved by universal PCR primers (MY09/11 oligonucleotides). Then sequencing and phylogenetic tree was constructed. Results: Nine samples were found positive and detected by conventional PCR, they were identified in CIN1 and SCC at 7.5% (n=3) for each, 5.0% (n=2) KA, and 2.5% (n=1) in CIN3 cases, after sequencing were submitted to GenBank and accession numbers were obtained. The phylogenetic tree was constructed and the aligned sequences showed high homology with the nucleotide sequence of the references from the Genbank database. HPV 11, 16, 18, 22, 33, 52, and 58 were found to have little nucleotide heterogeneity and thus no amino acid heterogeneity. Conclusion: Sequencing and phylogenetic analysis of circulating HPV types in Duhok provides very essential data about nucleotides and amino acid heterogeneity, to reveal genetic diversity with strains included in the vaccines that have not been introduced to Iraq yet.

[1]  R. Roden,et al.  Cervical Cancer Immunotherapy: Facts and Hopes , 2021, Clinical Cancer Research.

[2]  S. Rodenhuis,et al.  Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site , 2020, British Journal of Cancer.

[3]  Moganavelli Singh,et al.  Cervical cancer: a meta-analysis, therapy and future of nanomedicine , 2020, Ecancermedicalscience.

[4]  M. Capobianchi,et al.  The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease , 2020, Frontiers in Immunology.

[5]  T. Muderris,et al.  HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey , 2019, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[6]  M. Karimian,et al.  Association of Some High-Risk Mucosal Types of Human Papillomavirus with Cutaneous Squamous Cell Carcinoma in an Iranian Population , 2019, Iranian journal of pathology.

[7]  Yiqun Liao,et al.  Profile of MeltPro® HPV test for human papillomavirus genotyping and cervical precancer screening , 2019, Expert review of molecular diagnostics.

[8]  M. Sopian,et al.  Obstacles to Implementing the HPV Vaccine: Is it Worth Pursuing or Not? , 2019, Asian Pacific Journal of Cancer Care.

[9]  I. Pity,et al.  Human Papillomavirus Genotyping among Different Cervical Smears in Duhok/Iraq , 2019, Asian Pacific journal of cancer prevention : APJCP.

[10]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[11]  J. Dillner,et al.  Towards quality and order in human papillomavirus research. , 2018, Virology.

[12]  A. Amirzargar,et al.  Retrospective Analysis of Prevalence of High-risk and Low-risk Human Papillomavirus (HPV) Genotypes in Iranian Women During 2013-2016 , 2017 .

[13]  S. Jalilian,et al.  The Prevalence and Genotype Distribution of Human Papillomavirus Types in the General Female Population in West of Iran , 2017 .

[14]  Fabiana Botelho de Miranda Onofre,et al.  HPV detection using primers MY09/MY11 and GP5+/GP6+ in patients with cytologic and/or colposcopic changes , 2014 .

[15]  M. Shoukri,et al.  Human papillomaviruses in cervical specimens of women residing in Riyadh, Saudi Arabia: a hospital-based study. , 2014, Journal of infection in developing countries.

[16]  K. Kapila,et al.  Viral load of human papillomavirus in women with normal and abnormal cervical cytology in Kuwait. , 2013, Journal of infection in developing countries.

[17]  A. Giuliano,et al.  Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study , 2011, The Lancet.

[18]  J. Bogers,et al.  Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types , 2007, Journal of cellular and molecular medicine.

[19]  U. Liebert,et al.  PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[20]  F. Bir,et al.  [Investigation of human papillomavirus DNA in cervical specimens by hybrid capture assay]. , 2004, Mikrobiyoloji bulteni.

[21]  T. Iftner,et al.  Chapter 12: Human papillomavirus technologies. , 2003, Journal of the National Cancer Institute. Monographs.

[22]  David R. Scott,et al.  Improved Amplification of Genital Human Papillomaviruses , 2000, Journal of Clinical Microbiology.

[23]  Nadya Y. Ahmed,et al.  Prevalence of HPV Immunostaining in Benign, Preneoplastic & Neoplastic Cervical Lesions of Kurdish Women in Erbil City/Kurdistan of Iraq , 2014 .

[24]  Sunanda Ghosh,et al.  Evaluation of Pap smear , high risk HPV DNA testing in detection of cervical neoplasia with colposcopy guided or conventional biopsy as gold standard , 2014 .